In recent years, the debate over net price transparency (NPT) has intensified with organisations leading calls for greater transparency of net prices in the pharmaceutical sector. In a study funded by Merck Sharp & Dohme, an expert panel coordinated by CRA developed evidence on the impact of greater NPT on innovative medicines in Europe.
Ending the HIV epidemic: Ensuring equitable access to innovative HIV treatment and care
While advances in prevention, testing, and treatment have transformed outcomes for many people living with or at risk of HIV, significant inequities continue...